Ben Burnett
Analyst
Wells Fargo
Equibles does not estimate personal net worth.
About Ben Burnett
Ben Burnett is recorded as Analyst at Wells Fargo. Ben Burnett has spoken on 12 earnings calls and 4 other investor events across 10 companies, most recently for Mannkind Corp on November 5, 2026. Those appearances were for Axsome Therapeutics, Inc. (AXSM), Mannkind Corp (MNKD), Ptc Therapeutics, Inc. (PTCT), UNITED THERAPEUTICS Corp (UTHR), Praxis Precision Medicines, Inc. (PRAX) and 5 other companies. The companies whose calls Ben Burnett spoke on are classified in the Healthcare sector.
Ben Burnett on recent calls
“It looks like you're seeing an acceleration in ferocic scripts, which is really interesting, if I understood that chart correctly. Just curious if maybe you could quantify that growth, and also, where is this coming from?”
“I also wanted to ask a DTX 301 OTC question. Can you talk about the design of the open label portion of the Phase III, and what is the complete responder rate that's needed for statistical success here?”
“Just want to know if you can maybe talk about sort of what the new top-line guidance contemplates.”
“Just one on OO6 and AATD, just the registrational study that's being planned. Can you talk about what endpoints might support full approval? And I guess are some of these endpoints easier to power forward than others?”
Affiliation history
-
Wells Fargo
Analyst
Transcript header (unverified)
Current
Company network
MNKD
Biotechnology · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
INSM
Biotechnology · Healthcare
ALKS
Drug Manufacturers - Specialty & Generic · Healthcare